Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
7,400.96
(
-0.16%
)
US TECH 100
28,493.60
(
0.72%
)
Dow Jones
49,760.56
(
0.11%
)
Brent Oil
105.38
(
-0.36%
)
Bitcoin
81,233.33
(
0.92%
)
News Focus
News Focus
Post# of 257553
Next 10
Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 843
Posts 122973
Boards Moderated 9
Alias Born 09/05/2002

DewDiligence

Member Level

Re: dewophile post# 191721

Tuesday, 05/26/2015 5:51:49 PM

Tuesday, May 26, 2015 5:51:49 PM

Post# of 257553
Thx for feedback. Based on JNP's CC, management thinks the future of the company lies in the newly in-licensed (potentially multi-drug) IVR. Crinone and the existing delivery mechanism will keep the company funded while it develops the IVR for applications that have yet to be disclosed.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next

Discover What Traders Are Watching

Explore small cap ideas before they hit the headlines.

Join Today